---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-082184"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:55:56.330239+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Q3 net loss $8.6M; XPro Phase II AD trial advances, INKmune on track

## Summary
- Net loss $8.6M vs $7.7M YoY; R&D $6.0M; cash $41.8M as of Sept 30.
- MHRA authorized XPro Phase II trial in early AD; recruitment increasing; top-line results expected end-2024.
- FDA clinical hold on XPro for CNS expected to be lifted by end-2023.
- INKmune Phase I/II in mCRPC to enroll first patient by year-end 2023; LAUREL trial in MDS/AML third site active.

## SEC filing metadata
- accession: 0001213900-23-082184
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/0001213900-23-082184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/ea187584-8k_inmunebio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-082184
- JSON: https://secwatch.observer/filing/0001213900-23-082184.json
- Plain text: https://secwatch.observer/filing/0001213900-23-082184.txt

## Key facts
- Earnings Releases
  Inmune Bio, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 1, 2023, INmune Bio Inc. (the “Company”), issued a press release announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390023082184/0001213900-23-082184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.